International Clinical Trial: A Phase III, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Subretinal Injection of LX102 in Participants with Neovascular Age-Related Macular Degeneration - The STELLAR Trial

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115643) titled 'A Phase III, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Subretinal Injection of LX102 in Participants with Neovascular Age-Related Macular Degeneration - The STELLAR Trial' on Dec. 29, 2025.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Shanghai General Hospital

Condition: Neovascular Age-Related Macular Degeneration

Intervention: LX102 group:LX102/Subretinal Injection

Recruitment Status: Recruiting

Phase: 3

Date of First Enrollment: 2026-01-01

Target Sample Size: LX102 group:166;Aflibercept group:166;

Countries of Recruitment:...